Q1 CERTIFICATES ex99.htm FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: 1. Review: I have reviewed the interim finan
Friday, June 3, 2011 BiopharmaWatch Research 1 min read
Key Takeaway: CERTIFICATION OF INTERIM FILINGS
I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following:
/s/ Brad Thompson Brad Thompson, PhD President and CEO
CERTIFICATION OF INTERIM FILINGS
I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the foll
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
7%
average across 3 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
REOLYSIN
Phase 3 · Carcinoma, Squamous Cell of the Head and Neck
Full Press Release Details
CERTIFICATION OF INTERIM FILINGS
I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following:
/s/ Brad Thompson
Brad Thompson, PhD
President and CEO
CERTIFICATION OF INTERIM FILINGS
I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the following: